You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 28, 2024

Details for Patent: 10,869,924

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,869,924 protect, and when does it expire?

Patent 10,869,924 protects INLYTA and is included in one NDA.

This patent has twenty patent family members in sixteen countries.

Summary for Patent: 10,869,924

Title:	PD-L1 antagonist combination treatments
Abstract:	The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
Inventor(s):	Andrews; Glen Ian (San Diego, CA), Chen; Shihao (Foster City, CA), Di Pietro; Alessandra (Opera, IT), Fontana; David (Clyde Hill, WA), Goldberg; Zelanna (San Diego, CA), Lin; Chia-Yang (Palo Alto, CA), Long; Hua (San Carlos, CA), Martignoni; Marcella (Milan, IT), Nuyten; Dimitry Serge Antoine (San Francisco, CA), Thall; Aron David (San Diego, CA), Woolfson; Adrian (New York, NY)
Assignee:	MERCK PATENT GMBH (Darmstadt, DE) PFIZER INC. (New York, NY)
Application Number:	15/736,615
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,869,924

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-001	Jan 27, 2012		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				AXITINIB IN COMBINATION WITH AVELUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA	⤷ Try a Trial
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-002	Jan 27, 2012		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				AXITINIB IN COMBINATION WITH AVELUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 10,869,924

PCT Information
PCT Filed	June 15, 2016	PCT Application Number:	PCT/US2016/037498
PCT Publication Date:	December 22, 2016	PCT Publication Number:	WO2016/205277

International Family Members for US Patent 10,869,924

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016280003	⤷ Try a Trial
Canada	2989586	⤷ Try a Trial
China	107750166	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.